risperidone has been researched along with Tics in 12 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
Tics: Habitual, repeated, rapid contraction of certain muscles, resulting in stereotyped individualized actions that can be voluntarily suppressed for only brief periods. They often involve the face, vocal cords, neck, and less often the extremities. Examples include repetitive throat clearing, vocalizations, sniffing, pursing the lips, and excessive blinking. Tics tend to be aggravated by emotional stress. When frequent they may interfere with speech and INTERPERSONAL RELATIONS. Conditions which feature frequent and prominent tics as a primary manifestation of disease are referred to as TIC DISORDERS. (From Adams et al., Principles of Neurology, 6th ed, pp109-10)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the efficacy and safety of risperidone in children and adults with Tourette syndrome." | 9.10 | A placebo-controlled trial of risperidone in Tourette syndrome. ( Katsovich, L; Leckman, JF; Peterson, BS; Scahill, L; Schultz, RT, 2003) |
| "These results suggest that OCD patients with and without comorbid chronic tic disorders or schizotypal personality disorder may respond to the addition of low-dose risperidone to ongoing SRI therapy." | 9.09 | A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. ( Epperson, CN; McDougle, CJ; Pelton, GH; Price, LH; Wasylink, S, 2000) |
| "To evaluate the efficacy and harms of pimozide in comparison to placebo or other medications in the treatment of tics in Tourette Syndrome." | 8.85 | Pimozide for tics in Tourette's syndrome. ( Marras, C; Pringsheim, T, 2009) |
| "To evaluate the efficacy and safety of risperidone in children and adults with Tourette syndrome." | 5.10 | A placebo-controlled trial of risperidone in Tourette syndrome. ( Katsovich, L; Leckman, JF; Peterson, BS; Scahill, L; Schultz, RT, 2003) |
| "These results suggest that OCD patients with and without comorbid chronic tic disorders or schizotypal personality disorder may respond to the addition of low-dose risperidone to ongoing SRI therapy." | 5.09 | A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. ( Epperson, CN; McDougle, CJ; Pelton, GH; Price, LH; Wasylink, S, 2000) |
| "To evaluate the efficacy and harms of pimozide in comparison to placebo or other medications in the treatment of tics in Tourette Syndrome." | 4.85 | Pimozide for tics in Tourette's syndrome. ( Marras, C; Pringsheim, T, 2009) |
| "The aim of this study is to assess efficacy of augmentation of SSRIs with risperidone or aripiprazole in youths with tic-related Obsessive-Compulsive Disorder (OCD) non responders to an SSRI monotherapy." | 3.79 | Antipsychotic augmentation of selective serotonin reuptake inhibitors in resistant tic-related obsessive-compulsive disorder in children and adolescents: a naturalistic comparative study. ( Brovedani, P; Masi, G; Pfanner, C, 2013) |
| "In clinical practice guidelines there is no consensus about the medications that should be initially offered to children and young people with Tourette's syndrome." | 3.01 | Comparative efficacy, tolerability, and acceptability of pharmacological interventions for the treatment of children, adolescents, and young adults with Tourette's syndrome: a systematic review and network meta-analysis. ( Behling, E; Bloch, MH; Farhat, LC; Landeros-Weisenberger, A; Levine, JLS; Macul Ferreira de Barros, P; Wang, Z, 2023) |
| "We reviewed articles in English dealing with research into the effect of atypical antipsychotic drugs on tic reduction in Tourette's syndrome." | 2.41 | [Treatment of tics in Tourette syndrome with atypical antipsychotic drugs]. ( Jørgensen, JI; Sindø, I, 2002) |
| "We used a systematic survey to collate the consensus of Japanese experts and compare it with the recent international evidence." | 1.51 | Expert consensus on pharmacotherapy for tic disorders in Japan. ( Fujio, M; Hamamoto, Y; Kano, Y; Kono, T; Matsuda, N; Nonaka, M, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (66.67) | 29.6817 |
| 2010's | 3 (25.00) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Farhat, LC | 2 |
| Behling, E | 2 |
| Landeros-Weisenberger, A | 2 |
| Levine, JLS | 2 |
| Macul Ferreira de Barros, P | 2 |
| Wang, Z | 2 |
| Bloch, MH | 2 |
| Hamamoto, Y | 1 |
| Fujio, M | 1 |
| Nonaka, M | 1 |
| Matsuda, N | 1 |
| Kono, T | 1 |
| Kano, Y | 1 |
| Masi, G | 1 |
| Pfanner, C | 1 |
| Brovedani, P | 1 |
| Pringsheim, T | 1 |
| Marras, C | 1 |
| Tavano, A | 1 |
| Busan, P | 1 |
| Borelli, M | 1 |
| Pelamatti, G | 1 |
| Sindø, I | 1 |
| Jørgensen, JI | 1 |
| Listernick, R | 1 |
| Scahill, L | 1 |
| Leckman, JF | 1 |
| Schultz, RT | 1 |
| Katsovich, L | 1 |
| Peterson, BS | 1 |
| Railton, CJ | 1 |
| Kapur, B | 1 |
| Koren, G | 1 |
| Feroz-Nainar, C | 1 |
| Roy, M | 1 |
| McDougle, CJ | 1 |
| Epperson, CN | 1 |
| Pelton, GH | 1 |
| Wasylink, S | 1 |
| Price, LH | 1 |
| Sandor, P | 1 |
| Stephens, RJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Transcranial Magnetic Stimulation for Individuals With Tourette's Syndrome[NCT00529308] | Phase 2 | 20 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The CGI-I is a clinician-rated scales that have been used in clinical trials for over 25 years. Clinicians rate patient improvement compared to baseline. By convention, 4 = No Change; scores of 5, 6, and 7 move in the direction of worsening; scores of 3, 2, and 1 correspond to Minimal Improvement, Much Improved or Very Much Improved, respectively. CGI-I ratings of Much or Very Much Improved at post-treatment are used to identify treatment responders." (NCT00529308)
Timeframe: 3 weeks
| Intervention | participants (Number) |
|---|---|
| Active | 2 |
| Sham | 8 |
"The CGI-I is a clinician-rated scales that have been used in clinical trials for over 25 years. Clinicians rate patient improvement compared to baseline. By convention, 4 = No Change; scores of 5, 6, and 7 move in the direction of worsening; scores of 3, 2, and 1 correspond to Minimal Improvement, Much Improved or Very Much Improved, respectively. CGI-I ratings of Much or Very Much Improved at post-treatment are used to identify treatment responders." (NCT00529308)
Timeframe: 3 weeks
| Intervention | participants (Number) |
|---|---|
| Active | 1 |
| Sham | 0 |
Motor Threshold (MT) is thought to be a measure of membrane excitability in pyramidal neurons. MT is defined as the minimum magnetic flux needed to elicit a threshold EMG response (50 µV in peak to peak amplitude) in a resting target muscle in 5 out of 10 trials using single pulse TMS administered to the contralateral primary motor cortex. MT for both right and left hand are determined, and the lowest is used to select the intensity for rTMS. (NCT00529308)
Timeframe: 3 weeks
| Intervention | µV (Mean) |
|---|---|
| Active | 56.5 |
| Sham | 63.8 |
Motor Threshold (MT) is thought to be a measure of membrane excitability in pyramidal neurons. MT is defined as the minimum magnetic flux needed to elicit a threshold EMG response (50 µV in peak to peak amplitude) in a resting target muscle in 5 out of 10 trials using single pulse TMS administered to the contralateral primary motor cortex. MT for both right and left hand are determined, and the lowest is used to select the intensity for rTMS. (NCT00529308)
Timeframe: 3 weeks
| Intervention | µV (Mean) |
|---|---|
| Active | 56 |
| Sham | 59.8 |
Y-GTSS is a clinician-rated scale used to assess tic severity. Motor and phonic tics are rated separately from 0 to 5 on several scales including number, frequency, intensity, complexity, and interference. Thus Motor and Phonic Tic scores can range from 0 to 25; the combined Total Tic Score ranges from 0 to 50. There is also an Impairment score that rates the overall burden due to tics. The Impairment scale yields a single score from 0 to 50 with higher scores indicating higher levels of overall impairment associated with tics. (NCT00529308)
Timeframe: 3 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Active | 29.5 |
| Sham | 31.5 |
3 reviews available for risperidone and Tics
| Article | Year |
|---|---|
Comparative efficacy, tolerability, and acceptability of pharmacological interventions for the treatment of children, adolescents, and young adults with Tourette's syndrome: a systematic review and network meta-analysis.
Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Antipsychotic Agents; Aripiprazole; Child; Clonidi | 2023 |
Comparative efficacy, tolerability, and acceptability of pharmacological interventions for the treatment of children, adolescents, and young adults with Tourette's syndrome: a systematic review and network meta-analysis.
Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Antipsychotic Agents; Aripiprazole; Child; Clonidi | 2023 |
Comparative efficacy, tolerability, and acceptability of pharmacological interventions for the treatment of children, adolescents, and young adults with Tourette's syndrome: a systematic review and network meta-analysis.
Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Antipsychotic Agents; Aripiprazole; Child; Clonidi | 2023 |
Comparative efficacy, tolerability, and acceptability of pharmacological interventions for the treatment of children, adolescents, and young adults with Tourette's syndrome: a systematic review and network meta-analysis.
Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Antipsychotic Agents; Aripiprazole; Child; Clonidi | 2023 |
Pimozide for tics in Tourette's syndrome.
Topics: Anti-Dyskinesia Agents; Haloperidol; Humans; Pimozide; Randomized Controlled Trials as Topic; Risper | 2009 |
[Treatment of tics in Tourette syndrome with atypical antipsychotic drugs].
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Dopamine Antagonists; Humans; Olanzapine; Pirenzep | 2002 |
2 trials available for risperidone and Tics
| Article | Year |
|---|---|
A placebo-controlled trial of risperidone in Tourette syndrome.
Topics: Adolescent; Adult; Antipsychotic Agents; Body Weight; Child; Diagnostic Techniques, Neurological; Do | 2003 |
A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder.
Topics: Adult; Antipsychotic Agents; Comorbidity; Dopamine Antagonists; Double-Blind Method; Drug Administra | 2000 |
7 other studies available for risperidone and Tics
| Article | Year |
|---|---|
Expert consensus on pharmacotherapy for tic disorders in Japan.
Topics: Adult; Aged; Aripiprazole; Attention Deficit Disorder with Hyperactivity; Comorbidity; Consensus; Dr | 2019 |
Antipsychotic augmentation of selective serotonin reuptake inhibitors in resistant tic-related obsessive-compulsive disorder in children and adolescents: a naturalistic comparative study.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Chi-Square Distribution; Child; Drug Synergism; Fema | 2013 |
Risperidone reduces tic-like motor behaviors and linguistic dysfluencies in severe persistent developmental stuttering.
Topics: Humans; Language Development Disorders; Linguistics; Male; Risperidone; Severity of Illness Index; S | 2011 |
A nine-year-old girl with new-onset tics.
Topics: Antipsychotic Agents; Child; Chorea; Clonidine; Diagnosis, Differential; Female; Humans; Obsessive-C | 2003 |
Subtherapeutic risperidone serum concentrations in an adolescent during hemodialysis: a pharmacological puzzle.
Topics: Adolescent; Antipsychotic Agents; Drug Monitoring; Female; Humans; Isoxazoles; Paliperidone Palmitat | 2005 |
Risperidone and late onset tics.
Topics: Adolescent; Antipsychotic Agents; Autistic Disorder; Child; Dyskinesia, Drug-Induced; Female; Follow | 2006 |
Risperidone treatment of aggressive behavior in children with Tourette syndrome.
Topics: Adolescent; Aggression; Antipsychotic Agents; Child; Child, Preschool; Female; Humans; Male; Retrosp | 2000 |